Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — clinical trials in Italy
Prefer to look first? Browse the live map without signing up.
30 open options
- TRIALPHASE3RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
KarXT — 429 sites
- TRIALPHASE3RECRUITING
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Acoramidis · Placebo oral tablet — 104 sites
- TRIALNAENROLLING_BY_INVITATION
The Role of Advanced Electroencephalographic Data as Marker of Pathology and Prognosis in Primary Dementias
Electroencephalogram · 3 Tesla MRI · Apolipoprotein E genetic test — 1 site
- TRIALNARECRUITING
Training App for Inhibitory Control Towards Food
Food-specific inhibitory control training delivered through the FoodTraining App · Waiting list — 1 site
- TRIALNARECRUITING
Next-Generation alzheImer'S Therapeutics
genetically encoded engineered proteins — 1 site
- TRIALPHASE2RECRUITING
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
ML-007C-MA · Placebo — 55 sites
- TRIALNARECRUITING
Effectiveness of TeleVR App in Cognitive Decline and MCI Patients
Telerehabilitation with Virtual Reality · Traditional Cognitive Rehabilitation — 1 site
- TRIALNARECRUITING
EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069
RICORDO-DTx · Home-based unstructured cognitive stimulation — 3 sites
- TRIALPHASE2RECRUITING
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
VHB937 · VHB937 · Placebo — 74 sites
- TRIALNARECRUITING
Validation of a Digital Intervention to Rehabilitate Cognitive Resources
RICORDO · Treatment as Usual (TAU) — 1 site
- TRIALNARECRUITING
Evaluation of the Impact of Medium-chain Fatty Acids in the Evolution of Newly Diagnosed Mild Cognitive Impairment
Mediterranean-type diet with MCT supplementation · Mediterranean-type food regimen using extra virgin olive oil — 1 site
- TRIALPHASE3ENROLLING_BY_INVITATION
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
ACP-204 — 76 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
KarXT · KarX-EC · Placebo — 119 sites
- TRIALNANOT_YET_RECRUITING
Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance
MRI assessment and blood sample collection — 1 site
- TRIALPHASE3RECRUITING
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
KarXT · Placebo — 296 sites
- TRIALNARECRUITING
Transcranial Pulse Stimulation. a Potential Treatment for Early Dementia
Transcranial Pulse Stimulation — 2 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug · Matching Placebo (Remternetug) — 37 sites
- TRIALPHASE3RECRUITING
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
No Intervention — 229 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug (SC) · Matching Placebo (Remternetug) — 37 sites
- TRIALNARECRUITING
A Multifocal tDCS-EEG Protocol for Improving Symptoms of Mild Cognitive Impairment and Early Dementia
StarStim 32, Neuroelectrics, Spain - Real multifocal tDCS · StarStim 32, Neuroelectrics, Spain - Sham multifocal tDCS · Cognitive treatment — 1 site
- TRIALNARECRUITING
Longitudinal Profiling of Plasma-Derived Glial Extracellular Vesicles in Alzheimer's Disease
blood sampling — 1 site
- TRIALNARECRUITING
Novel Personalized Non Invasive Combined Magnetic and Electrical Stimulation of the DMN in Mild AD Patients
Combined iTBS-tACS · iTBS-sham tACS · sham iTBS- sham tACS — 2 sites
- TRIALNARECRUITING
Personalized Digital Training for COGnitive FITness in Mild Cognitive Impairment
RICORDO · S.A.M.B.A. — 2 sites
- TRIALNANOT_YET_RECRUITING
Physical Exercise to Prevent Mild-cognitive Impairment in Patients With Kidney Disfunctions
Exercise · Control (Standard treatment) — 6 sites
- TRIALNARECRUITING
Financial Abilities in Neurological Diseases. Development of a Telerehabilitation Program: FINAGE
Telerehabilitation group · Conventioanl treatment group — 1 site
- TRIALPHASE3RECRUITING
A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease
Rotigotine 4Mg/24Hrs Patch · Placebo — 1 site
- TRIALNARECRUITING
Transcranial Alternating Current Stimulation (tACS) Combined With Cognitive Training in Alzheimer's Disease
Transcranial Alternating Current Stimulation · Sham Transcranial Alternating Current Stimulation · Individualized Computerized Memory Training — 2 sites
- TRIALNARECRUITING
A Multimodal Approach for Clinical Diagnosis and Treatment of Primary Progressive Aphasia, MAINSTREAM ID:3430931
Active tDCS · individualized language training · Placebo tDCS — 4 sites
- TRIALPHASE2 / PHASE3RECRUITING
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
EXV-802 · Placebo · EXV-801 — 49 sites
- TRIALNARECRUITING
Silver Agri Age: Longevity, Intrinsic Capacity and Cognitive Impairment Into Farmlands and Natural Environments: Updating Contexts Following the "Montessori" Action
Social activities with cognitive stimulation — 2 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.